Gastrointestinale Mikrobiota und Tumorerkrankungen – ein „pas de deux“?

Abstract

Malignant diseases pose an enormous challenge to today’s health care system. Advanced pathophysiological understanding of gastrointestinal microbiota and a viable, causal relation to the development of malignant tumors is increasingly becoming the focus of medical research. The following article presents key pathomechanisms of reciprocal interaction between microbiota and malignancy and illustrates the associated role of diet.

Tumorerkrankungen stellen unser heutiges Gesundheitssystem vor große Herausforderungen. Das in den letzten Dekaden gewachsene pathophysiologische Verständnis der gastrointestinalen Mikrobiota und ein möglicher kausaler Zusammenhang mit der Entstehung von Malignomen rücken daher zunehmend in den Fokus der Forschung. Der folgende Beitrag gibt einen Einblick in zahlreiche Pathomechanismen, über die sich Mikrobiota und Malignome gegenseitig beeinflussen, und beleuchtet außerdem die Rolle der Ernährung in diesem System.

Schlüsselwörter

Gastrointestinale Mikrobiota - Kolorektales Karzinom (KRK) - Ernährung

Key words

Gastrointestinal microbiota - Colorectal cancer (CRC) - Diet

• Literatur

• 1 Zeißig S. Die physiologische Standortflora. In: Stallmach A. Vehreschild MJ. editors Mikrobiom: Wissenstand und Perspektiven. Berlin/Boston: De Gruyter; 2016: 61-77
• 2 Qin J. Li R. Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65
• 3 Kaatsch P. Spix C. Caspritz S. et al. Krebs in Deutschland 2011/2012. Berlin; 2015. Im Internet: http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015 / krebs_in_deutschland_2015.pdf?__blob=publicationFile Stand: 26.11.2016
• 4 Weisburger JH. Reddy BS. Narisawa T. et al. Germ-free status and colon tumor induction by N-methyl-N'-nitro-N-nitrosoguanidine. Proc Soc Exp Biol Med 1975; 148: 1119-1121
• 5 Yoshimoto S. Loo TM. Atarashi K. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101
• 6 Xuan C. Shamonki JM. Chung A. et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014; 9: e83744
• 7 Abdulamir AS. Hafidh RR. Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res 2011; 30: 11
• 8 Balamurugan R. Rajendiran E. George S. et al. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 2008; 23: 1298-1303
• 9 Castellarin M. Warren RL. Freeman JD. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306
• 10 Feng Q. Liang S. Jia H. et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 2015; 6: 6528
• 11 Sears CL. Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014; 15: 317-328
• 12 Lasry A. Ben-Neriah Y. Senescence-associated inflammatory responses: aging and cancer perspectives. Trends Immunol 2015; 36: 217-228
• 13 West NR. McCuaig S. Franchini F. et al. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 2015; 15: 615-629
• 14 Peuker K. Muff S. Wang J. et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor development. Nat Med 2016; 22: 506-515
• 15 Adami J. Gabel H. Lindelof B. et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227
• 16 Dantal J. Hourmant M. Cantarovich D. et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628
• 17 Schwabe RF. Jobin C. The microbiome and cancer. Nat Rev Cancer 2013; 13: 800-812
• 18 Pflug N. Stellenwert des Mikrobioms in der Genese und Therapie von hämatologischen und onkologischen Erkrankungen. In: Stallmach A. Vehreschild MJ. eds. Mikrobiom: Wissenstand und Perspektiven. Berlin/Boston: De Gruyter; 2016: 233-255
• 19 Gagniere J. Raisch J. Veziant J. et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016; 22: 501-518
• 20 Tjalsma H. Boleij A. Marchesi JR. et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-582
• 21 Iida N. Dzutsev A. Stewart CA. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970
• 22 Viaud S. Saccheri F. Mignot G. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976
• 23 Pflug N. Kluth S. Vehreschild JJ. et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology 2016; 5: e1150399
• 24 Pohl M. Schmiegel W. Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. Dig Dis 2016; 34: 574-579
• 25 Sivan A. Corrales L. Hubert N. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084-1089
• 26 Le Marchand L. Kolonel LN. Cancer in Japanese migrants to Hawaii: interaction between genes and environment. Rev Epidemiol Sante Publique 1992; 40: 425-430
• 27 Ou J. Carbonero F. Zoetendal EG. et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr 2013; 98: 111-120
• 28 David LA. Maurice CF. Carmody RN. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-563
• 29 O'Keefe SJ. Li JV. Lahti L. et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015; 6: 6342
• 30 Vétizou M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079-1084